These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study. Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409 [TBL] [Abstract][Full Text] [Related]
24. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. Deps P; Guerra P; Nasser S; Simon M Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031 [TBL] [Abstract][Full Text] [Related]
25. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. Sapkota BR; Shrestha K; Pandey B; Walker SL Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore. Lim JT; Tan T Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116 [TBL] [Abstract][Full Text] [Related]
27. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil. Maia MV; Cunha Mda G; Cunha CS An Bras Dermatol; 2013; 88(2):205-10. PubMed ID: 23739719 [TBL] [Abstract][Full Text] [Related]
28. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Mane I; Cartel JL; Grosset JH Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595 [TBL] [Abstract][Full Text] [Related]
29. Ofloxacin-Containing Multidrug Therapy in Ambulatory Leprosy Patients: A Case Series. Faust L; Klowak M; MacRae C; Kopalakrishnan S; Showler AJ; Boggild AK J Cutan Med Surg; 2021; 25(1):45-52. PubMed ID: 32869655 [TBL] [Abstract][Full Text] [Related]
30. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment. Prasad PV; Babu A; Kaviarasan PK; Viswanathan P; Tippoo R Indian J Dermatol Venereol Leprol; 2005; 71(4):242-5. PubMed ID: 16394431 [TBL] [Abstract][Full Text] [Related]
31. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Pönnighaus JM; Boerrigter G Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703 [TBL] [Abstract][Full Text] [Related]
32. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy. Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892 [TBL] [Abstract][Full Text] [Related]
33. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation. Rao PN; Suneetha S; Pratap DV Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618 [TBL] [Abstract][Full Text] [Related]
34. A study on the impact of FD-MDT on 200 leprosy patients. Vara N; Marfatiya Y Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520 [TBL] [Abstract][Full Text] [Related]
35. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633 [TBL] [Abstract][Full Text] [Related]
36. Experience with multidrug therapy in paucibacillary leprosy. Bhate RD; Gupta CM; Chattopadhyay SP; Singh IP Indian J Lepr; 1986; 58(2):244-50. PubMed ID: 3805797 [TBL] [Abstract][Full Text] [Related]
37. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink M Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281 [TBL] [Abstract][Full Text] [Related]
38. Multidrug therapy--the pathway for global leprosy elimination. al-Qubati Y; al-Kubati AS Indian J Lepr; 2000; 72(4):477-90. PubMed ID: 11212482 [TBL] [Abstract][Full Text] [Related]
39. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai. Shetty VP; Wakade AV; Ghate SD; Pai VV Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931 [TBL] [Abstract][Full Text] [Related]
40. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink M Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]